messag updat estim follow
result model tweak reflect current spend rate pt
incras
reduc price-to-earnings target multipl
revenu estim move
respect
decreas price-to-earnings target multipl assum
trade premium peer compani revenu
estim move
respect pt increas prior
valuat risk
reduc price-to-earnings target multipl potenti
complement franchis headwind well increas cost associ recent bd
activ put discount averag price-to-earnings multipl peer
compani maintain neutral rate see major catalyst
near intermedi term weak metabol sale patient transit
soliris-to-ultomiri result lower revenu per patient
risk downsid risk includ slower expect growth
neuromuscular franchis inabl capit recent bd activ upsid
risk includ substanti larger expect growth soliri sale nmo
larg growth pnh/ahu popul treatment
valuat risk
updat model rais pt increas
pt due substanti out-performance compani across primari
product eylea dupix heavi attent compani gotten
effort drug kevzara attempt make antibodi
cocktail therapeut base success believ trade
ahead peer compani current trade price-to-earnings multipl
risk downsid risk includ failur secur approv eylea/dupixent/
libtayo addit indic rapid complet implement
like seri regul
page analyst certif import disclosur
compani report guggenheim secur llc estim
page analyst certif import disclosur
inc yatin suneja complement total yoy yoy metabol franchis qoq yoy total revenu gross oper oper incom non-gaap tax incom loss net incom net gaap qoq yoy ep exclud stock-comp item mm except per share unit
compani report guggenheim secur llc estim
page analyst certif import disclosur
yatin suneja chang chang chang chang sale record start chang chang productstot product chang chang collabor global sale start record global sale record global sale record ex-u sale cemiplimab record collabor eylea row chang chang ou revenu research chang chang collabor manufactur partner product stock-bas up-front stock-bas non-gaap non-gaap income/expens rate incom net incom chang chang basic dilut cash per debt per sharecash flow gener mm except pre share unit
issu research report guggenheim secur llc guggenheim secur research analyst whose name appear report
herebi certifi view express report accur reflect research analyst person view subject
secur issuer discuss herein ii part research analyst compens directli indirectli relat specif
recommend view express research analyst
research analyst whose name appear report receiv compens base upon variou factor includ qualiti research
investor client feedback guggenheim secur llc overal revenu includ invest bank revenu
guggenheim secur llc affili expect receiv intend seek compens invest bank servic alexion
pharmaceut inc inc next month
pleas refer websit company-specif disclosur referenc report http //guggenheimsecur bluematrix com/sellside/
disclosur action disclosur inform also avail complianc madison avenu new york ny
rate price target histori inc
creat bluematrix
rate price target histori inc
creat bluematrix
buy describ stock expect provid total return price appreci plu yield within period
neutral describ stock expect provid total return price appreci plu yield plu minu within
sell describ stock expect provid total neg return price appreci plu yield within period
page analyst certif import disclosur
